Galantamine in Alzheimer's disease.

Galantamine in Alzheimer's disease.

Galantamine is a cholinesterase inhibitor with a dual mechanism of action. It is a reversible inhibitor of acetylcholine esterase and enhances the intrinsic action of acetylcholine on nicotinic receptors, leading to increased cholinergic neurotransmission in the CNS. Galantamine has a large volume c...

Bibliografski detalji
Glavni autori:	Razay, G, Wilcock, G
Format:	Journal article
Jezik:	English
Izdano:	2008

Slični predmeti

The beneficial effects of galantamine on caregiver time in Alzheimer's disease
od: Sano, M, i dr.
Izdano: (2003)

The effects of galantamine treatment on caregiver time in Alzheimer's disease.
od: Sano, M, i dr.
Izdano: (2003)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
od: Wilcock, G, i dr.
Izdano: (2000)

Hyperinsulinaemia and Alzheimer's disease.
od: Razay, G, i dr.
Izdano: (1994)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
od: Wilcock, G, i dr.
Izdano: (2003)

Galantamine vs donepezil in the treatment of Alzheimer's disease.
od: Goldlist, B, i dr.
Izdano: (2003)

The metabolic syndrome and Alzheimer disease.
od: Razay, G, i dr.
Izdano: (2007)

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
od: Pirttilä, T, i dr.
Izdano: (2004)

A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: An intent-to-treat analysis
od: Wilcock, G, i dr.
Izdano: (2003)

Obesity, abdominal obesity and Alzheimer disease.
od: Razay, G, i dr.
Izdano: (2006)

Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies
od: Wilcock, G, i dr.
Izdano: (2002)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial (vol 321, pg 1445, 2000)
od: Wilcock, G
Izdano: (2001)

Insulin resistance, dyslipidemia and the risk of Alzheimer's disease: A case-control study
od: Razay, G, i dr.
Izdano: (2011)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
od: Yi-Ting Lin, i dr.
Izdano: (2019-05-01)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9) (1445-1449))
od: Wilcock, G
Izdano: (2001)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))
od: Wilcock, G
Izdano: (2001)

GALANTHAMINE AND THE TREATMENT OF ALZHEIMERS-DISEASE
od: Wilcock, G, i dr.
Izdano: (1993)

Can we predict the response to Galantamine in Alzheimer`s disease patients?
od: Carmen Gavan, i dr.
Izdano: (2015-09-01)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
od: Ben Seltzer
Izdano: (2009-12-01)

Effect of galantamine on time to residential or nursing home admission
od: Feldman, H, i dr.
Izdano: (2004)

Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study.
od: Razay, G, i dr.
Izdano: (2009)

Design and development of galantamine hydrobromide transdermal patch for treatment of alzheimer’s disease
od: Woo, Fong Yen
Izdano: (2015)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
od: Yasir Hasan Siddique, i dr.
Izdano: (2022-01-01)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
od: E Loveman, i dr.
Izdano: (2006-01-01)

Hierarchical adhesive hydrogel microparticles with galantamine hydrobromide encapsulation for the treatment of Alzheimer’s disease
od: Huijuan Zhou, i dr.
Izdano: (2024-10-01)

Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.
od: Joffres, C, i dr.
Izdano: (2003)

Safety and efficacy of galantamine in subjects with mild cognitive impairment.
od: Winblad, B, i dr.
Izdano: (2008)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
od: Mohd Adnan, i dr.
Izdano: (2023-09-01)

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy
od: Stavroula G. Nanaki, i dr.
Izdano: (2020-03-01)

Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data
od: Wilcock, G, i dr.
Izdano: (2002)

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review
od: J. Bryant, i dr.
Izdano: (2001-01-01)

Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
od: Soumee Bhattacharya, i dr.
Izdano: (2014-01-01)

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy
od: Dilyana Georgieva, i dr.
Izdano: (2023-03-01)

Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
od: Manickam Rajkumar, i dr.
Izdano: (2022-01-01)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
od: Hager K, i dr.
Izdano: (2014-10-01)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
od: Woo FY, i dr.
Izdano: (2015-06-01)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
od: Willian O Castillo, i dr.
Izdano: (2017-01-01)

Galantamine ameliorates experimental pancreatitis
od: Dane A. Thompson, i dr.
Izdano: (2023-10-01)

Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia
od: Emma D. Frost, i dr.
Izdano: (2024-11-01)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
od: Dan-Dan Li, i dr.
Izdano: (2019-05-01)